title: ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
creator: Ding, C
creator: Xu, J
creator: Li, J
subject: 320503 Clinical Pharmacology and Therapeutics
description: ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued.
date: 2008-05
type: Article
type: PeerReviewed
format: application/pdf
identifier: http://eprints.utas.edu.au/6553/1/ABT-874.pdf
relation: http://www.biomedcentral.com/1472-4472/9/515
identifier: Ding, C and Xu, J and Li, J (2008) ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Current Opinion in Investigational Drugs, 9 (5). pp. 515-522. ISSN 1472-4472
relation: http://eprints.utas.edu.au/6553/